Bicycle Therapeutics
Market Cap
US$575.9m
Last Updated
2021/01/19 00:10 UTC
Data Sources
Company Financials +
Executive Summary
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 10.1% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Excellent balance sheet with limited growth.
Share Price & News
How has Bicycle Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BCYC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: BCYC's weekly volatility (11%) has been stable over the past year.
Market Performance
7 Day Return
34.3%
BCYC
3.2%
US Biotechs
-0.4%
US Market
1 Year Return
141.3%
BCYC
36.8%
US Biotechs
19.5%
US Market
Return vs Industry: BCYC exceeded the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: BCYC exceeded the US Market which returned 19.6% over the past year.
Shareholder returns
| BCYC | Industry | Market | |
|---|---|---|---|
| 7 Day | 34.3% | 3.2% | -0.4% |
| 30 Day | 41.1% | 4.8% | 2.3% |
| 90 Day | 39.8% | 22.4% | 12.7% |
| 1 Year | 141.3%141.3% | 39.0%36.8% | 22.3%19.5% |
| 3 Year | n/a | 27.5%20.8% | 44.4%34.8% |
| 5 Year | n/a | 46.3%35.2% | 128.7%103.3% |
Long-Term Price Volatility Vs. Market
How volatile is Bicycle Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?2 months ago | Simply Wall St
Broker Revenue Forecasts For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher2 months ago | Simply Wall St
Bicycle Therapeutics plc (NASDAQ:BCYC) Just Reported And Analysts Have Been Lifting Their Price TargetsValuation
Is Bicycle Therapeutics undervalued compared to its fair value and its price relative to the market?
5.17x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BCYC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BCYC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BCYC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BCYC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BCYC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BCYC is overvalued based on its PB Ratio (5.2x) compared to the US Biotechs industry average (4.2x).
Next Steps
Future Growth
How is Bicycle Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
-10.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BCYC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BCYC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BCYC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BCYC's revenue (49.9% per year) is forecast to grow faster than the US market (10.3% per year).
High Growth Revenue: BCYC's revenue (49.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BCYC's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Bicycle Therapeutics performed over the past 5 years?
-26.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BCYC is currently unprofitable.
Growing Profit Margin: BCYC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BCYC is unprofitable, and losses have increased over the past 5 years at a rate of 26.5% per year.
Accelerating Growth: Unable to compare BCYC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCYC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: BCYC has a negative Return on Equity (-34.67%), as it is currently unprofitable.
Next Steps
Financial Health
How is Bicycle Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: BCYC's short term assets ($164.2M) exceed its short term liabilities ($17.0M).
Long Term Liabilities: BCYC's short term assets ($164.2M) exceed its long term liabilities ($43.5M).
Debt to Equity History and Analysis
Debt Level: BCYC's debt to equity ratio (13.2%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if BCYC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BCYC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BCYC has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 3.2% each year.
Next Steps
Dividend
What is Bicycle Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BCYC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BCYC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BCYC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BCYC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BCYC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Kevin Lee (51 yo)
5.33yrs
Tenure
US$4,376,297
Compensation
Dr. Kevin Lee, Ph.D. has been Chief Executive Officer of Bicycle Therapeutics Limited since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and Chie...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD4.38M) is above average for companies of similar size in the US market ($USD1.67M).
Compensation vs Earnings: Kevin's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.33yrs | US$4.38m | 1.24% $ 7.2m | |
| President & CFO | 2yrs | US$2.48m | 0% $ 0 | |
| Co-Founder | no data | US$23.95k | 0.77% $ 4.4m | |
| Chief Operating Officer | 5yrs | US$1.82m | 0.19% $ 1.1m | |
| Scientific Founder | no data | no data | no data | |
| Chief Scientific Officer | 4yrs | no data | 0% $ 0 | |
| General Counsel | 0.75yr | no data | no data | |
| Head of Clinical and Project Management | 4.67yrs | no data | no data | |
| President of U.S. and Chief Business Officer of U.S. | 4.67yrs | no data | no data | |
| Senior VP of Pre-Clinical Development | 2.17yrs | no data | no data | |
| Chief Business Officer | 1.33yrs | no data | no data | |
| Senior VP & Head of Clinical | 1.67yrs | no data | no data |
3.1yrs
Average Tenure
51yo
Average Age
Experienced Management: BCYC's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 5.33yrs | US$4.38m | 1.24% $ 7.2m | |
| Co-Founder | no data | US$23.95k | 0.77% $ 4.4m | |
| Independent Non-Executive Director | 6.25yrs | US$31.43k | 2.22% $ 12.8m | |
| Board Observer | 3.58yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.67yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 0.58yr | no data | no data | |
| Non-Executive Chairman | 1.83yrs | US$2.07m | 0.73% $ 4.2m | |
| Independent Non-Executive Director | 1.25yrs | US$179.69k | 0.11% $ 624.7k | |
| Independent Non-Executive Director | 1.5yrs | US$228.04k | 0.12% $ 696.7k | |
| Member of Scientific Advisory Board | 0.25yr | no data | no data | |
| Independent Non-Executive Director | 1.5yrs | US$212.33k | 0.12% $ 696.7k | |
| Member of Scientific Advisory Board | 2.67yrs | no data | no data |
1.8yrs
Average Tenure
65yo
Average Age
Experienced Board: BCYC's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19%.
Top Shareholders
Company Information
Bicycle Therapeutics plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Bicycle Therapeutics plc
- Ticker: BCYC
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$575.869m
- Shares outstanding: 21.30m
- Website: https://www.bicycletherapeutics.com
Number of Employees
Location
- Bicycle Therapeutics plc
- Babraham Research Campus
- Building 900
- Cambridge
- Cambridgeshire
- CB22 3AT
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BCYC | NasdaqGS (Nasdaq Global Select) | Yes | SPONSORED ADS | US | USD | May 2019 |
Biography
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicyc...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/19 00:10 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.